Q2 2017 13F Holders as of 6/30/2017
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
14.4M
-
Number of holders
-
151
-
Total 13F shares, excl. options
-
12.3M
-
Shares change
-
+545K
-
Total reported value, excl. options
-
$606M
-
Value change
-
+$28M
-
Put/Call ratio
-
0.26
-
Number of buys
-
75
-
Number of sells
-
-67
-
Price
-
$49.34
Significant Holders of Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK) as of Q2 2017
173 filings reported holding ANIK - Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share as of Q2 2017.
Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK) has 151 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12.3M shares
of 14.4M outstanding shares and own 85.23% of the company stock.
Largest 10 shareholders include BlackRock Inc. (1.79M shares), KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC (1.42M shares), WELLINGTON MANAGEMENT GROUP LLP (1.21M shares), DIMENSIONAL FUND ADVISORS LP (878K shares), VANGUARD GROUP INC (807K shares), Bank of New York Mellon Corp (490K shares), STATE STREET CORP (370K shares), AMI ASSET MANAGEMENT CORP (309K shares), COLUMBIA WANGER ASSET MANAGEMENT LLC (276K shares), and BTIM Corp. (262K shares).
This table shows the top 151 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.